Cargando…

Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk

HIV incidence continues to be unacceptably high in Eastern and Southern Africa, with women disproportionately affected. An increased per-contact risk of HIV acquisition among African, Caribbean, and other Black (ACB) women has been associated with the higher prevalence of bacterial vaginosis (BV) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Eric, Kaul, Rupert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665571/
https://www.ncbi.nlm.nih.gov/pubmed/34893070
http://dx.doi.org/10.1186/s40168-021-01183-x
_version_ 1784614036560674816
author Armstrong, Eric
Kaul, Rupert
author_facet Armstrong, Eric
Kaul, Rupert
author_sort Armstrong, Eric
collection PubMed
description HIV incidence continues to be unacceptably high in Eastern and Southern Africa, with women disproportionately affected. An increased per-contact risk of HIV acquisition among African, Caribbean, and other Black (ACB) women has been associated with the higher prevalence of bacterial vaginosis (BV) in these communities, wherein the vaginal microbiota is predominated by diverse pro-inflammatory anaerobic bacteria. However, while the vaginal microbiota in BV-free women is typically predominated by one of several different Lactobacillus spp., the degree of HIV protection afforded by a Lactobacillus-predominant vaginal microbiota also varies considerably. Specifically, L. crispatus is associated with an immunoregulatory genital immune environment, exclusion of BV-associated bacteria, and reduced HIV risk. In contrast, less HIV protection or exclusion of BV-associated bacteria and fewer immune benefits have been associated with L. iners—which is unfortunately the most common Lactobacillus species among ACB women. These species-specific clinical differences are underpinned by substantial genomic differences between Lactobacillus species: for instance, the much smaller genome of L. iners lacks the coding sequence for D-lactic acid dehydrogenase and cannot produce the D-lactate isomer that enhances HIV trapping in mucus but encodes for epithelial cell toxins and stress resistance proteins that may enhance bacterial survival in the context of microbiota and environmental fluctuations. While more studies are needed to elucidate whether differences in HIV protection between Lactobacillus species are due to direct genital immune effects or the exclusion of proinflammatory BV-associated bacteria, the current body of work suggests that for BV treatment to succeed as an HIV prevention strategy, it may be necessary to induce a vaginal microbiota that is predominated by specific (non-iners) Lactobacillus species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01183-x.
format Online
Article
Text
id pubmed-8665571
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86655712021-12-13 Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk Armstrong, Eric Kaul, Rupert Microbiome Review HIV incidence continues to be unacceptably high in Eastern and Southern Africa, with women disproportionately affected. An increased per-contact risk of HIV acquisition among African, Caribbean, and other Black (ACB) women has been associated with the higher prevalence of bacterial vaginosis (BV) in these communities, wherein the vaginal microbiota is predominated by diverse pro-inflammatory anaerobic bacteria. However, while the vaginal microbiota in BV-free women is typically predominated by one of several different Lactobacillus spp., the degree of HIV protection afforded by a Lactobacillus-predominant vaginal microbiota also varies considerably. Specifically, L. crispatus is associated with an immunoregulatory genital immune environment, exclusion of BV-associated bacteria, and reduced HIV risk. In contrast, less HIV protection or exclusion of BV-associated bacteria and fewer immune benefits have been associated with L. iners—which is unfortunately the most common Lactobacillus species among ACB women. These species-specific clinical differences are underpinned by substantial genomic differences between Lactobacillus species: for instance, the much smaller genome of L. iners lacks the coding sequence for D-lactic acid dehydrogenase and cannot produce the D-lactate isomer that enhances HIV trapping in mucus but encodes for epithelial cell toxins and stress resistance proteins that may enhance bacterial survival in the context of microbiota and environmental fluctuations. While more studies are needed to elucidate whether differences in HIV protection between Lactobacillus species are due to direct genital immune effects or the exclusion of proinflammatory BV-associated bacteria, the current body of work suggests that for BV treatment to succeed as an HIV prevention strategy, it may be necessary to induce a vaginal microbiota that is predominated by specific (non-iners) Lactobacillus species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01183-x. BioMed Central 2021-12-10 /pmc/articles/PMC8665571/ /pubmed/34893070 http://dx.doi.org/10.1186/s40168-021-01183-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Armstrong, Eric
Kaul, Rupert
Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
title Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
title_full Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
title_fullStr Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
title_full_unstemmed Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
title_short Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
title_sort beyond bacterial vaginosis: vaginal lactobacilli and hiv risk
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665571/
https://www.ncbi.nlm.nih.gov/pubmed/34893070
http://dx.doi.org/10.1186/s40168-021-01183-x
work_keys_str_mv AT armstrongeric beyondbacterialvaginosisvaginallactobacilliandhivrisk
AT kaulrupert beyondbacterialvaginosisvaginallactobacilliandhivrisk